Transaction details
Romeo R. Dizon, Iridex Corp's Chief Financial Officer, acquired 1,000 shares of the company's common stock at $1.46 per share on February 10, 2026, for a total outlay of $1,460. Following the purchase, Dizon's direct holdings in Iridex total 116,190 shares.
Preliminary results and cash flow
Iridex released preliminary unaudited figures indicating a year-end revenue increase in the fourth quarter of between 15% and 17%, translating to a revenue range of $14.6 million to $14.8 million. The company said it generated positive cash flow in the quarter and expects to report positive adjusted EBITDA for the full year of 2025.
Operational changes: headquarters relocation
The company plans to move its headquarters from Mountain View to San Jose, California. Management estimates the relocation will yield approximately $0.4 million in cost savings in fiscal 2026 and about $0.6 million in annual savings thereafter.
Clinical research
An independent study published in the journal Ophthalmology and Therapy assessed Iridex's MicroPulse transscleral laser technology for glaucoma retreatment and reported a notable reduction in intraocular pressure. The study was described as independent, and its findings were presented as evidence of the technology's effectiveness in the specific retreatment context.
Recent quarterly performance
In contrast to the preliminary fourth-quarter indicators, Iridex's Q3 2025 results included a net loss of $1.6 million, or $0.09 per share, which missed analysts' expectations for a $0.06 loss per share. Revenue in Q3 2025 was $12.5 million, below the forecasted $13.1 million. Despite those misses, the company indicated it remains focused on strategic initiatives and advancing its technologies.
Outlook and priorities
Taken together, the insider purchase, preliminary fourth-quarter revenue improvement, positive cash flow for the quarter, the planned headquarters move for cost savings, and independent clinical findings present a mix of operational and financial signals. Management has highlighted an expectation of positive adjusted EBITDA for full-year 2025 and continues to emphasize strategic and technological priorities.